Nicholas M. Pathoulas

Nicholas M. Pathoulas

Auto-generated profile, based on publicly available information

Nicholas M. Pathoulas

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2021 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
TEThomas L. Ekstrom
Thomas L. Ekstrom
NPNicholas M. Pathoulas
Nicholas M. Pathoulas
AHAmelia M. Huehls
Amelia M. Huehls
AKArun Kanakkanthara
Arun Kanakkanthara
LKLarry M. Karnitz
Larry M. Karnitz
Tumors with defective homologous recombination (HR) DNA repair are more sensitive to chemotherapies that induce lesions repaired by HR as well as PARP inhibitors (PARPis). However, these therapies have limited activity in HR-proficient cells. Accordingly, agents that disrupt HR may be a means to augment the activities of these therapies in HR-proficient tumors. Here we show that VLX600, a small molecule that has been in a phase I clinical trial, disrupts HR and synergizes with PARPis and platinum compounds in ovarian cancer cells. We further found that VLX600 and other iron chelators disrupt HR, in part, by inhibiting iron-dependent histone lysine demethylases (KDM) family members, thus blocking recruitment of HR repair proteins, including RAD51, to double-strand DNA breaks. Collectively, these findings suggest that pharmacologically targeting KDM family members with VLX600 may be a potential novel strategy to therapeutically induce HR defects in ovarian cancers and correspondingly sensitize them to platinum agents and PARPis, two standard-of-care therapies for ovarian cancer.

3 October 2025 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
VHVivek Hariharan
Vivek Hariharan
JWJennifer A. White
Jennifer A. White
FDFilippo Dragoni
Filippo Dragoni
EFEmily J. Fray
Emily J. Fray
NPNicholas Pathoulas
Nicholas Pathoulas
RSRobert F. Siliciano
Robert F. Siliciano
During replication of some RNA viruses, defective particles can spontaneously arise and interfere with wild-type (WT) virus replication. However, these defective interfering particles (DIPs) have not been reported in people with HIV-1 (PWH). Here we find DIPs in PWH who have a rare, polyclonal form of non-suppressible viraemia (NSV). We characterized the source of NSV in two PWH who never reached undetectable viral load despite adherence to antiretroviral therapy (ART). Remarkably, in each participant, we found a diverse set of defective viral genomes sharing the same fatal deletions. This paradoxical accumulation of mutations by viruses with fatal defects was driven by superinfection with intact viruses, resulting in mobilization of defective genomes and accumulation of additional mutations during untreated infection. These defective proviruses interfere with WT virus replication, conditionally replicate and, in one case, have an R 0 > 1, enabling in vivo spread. Despite this, clinical outcomes showed no beneficial effect of these DIPs. These findings demonstrate that fatally defective proviruses, traditionally considered evolutionary dead ends, can replicate and diversify upon superinfection without preventing disease progression.

3 April 2023
Verified
Other
Open access
TEThomas L. Ekstrom
Thomas L. Ekstrom
NPNicholas M. Pathoulas
Nicholas M. Pathoulas
AHAmelia M. Huehls
Amelia M. Huehls
AKArun Kanakkanthara
Arun Kanakkanthara
LKLarry M. Karnitz
Larry M. Karnitz
Supplementary Figures S1-S7, figure legends, and Tables S1 and S2.

3 April 2023
Verified
Other
Open access
TEThomas L. Ekstrom
Thomas L. Ekstrom
NPNicholas M. Pathoulas
Nicholas M. Pathoulas
AHAmelia M. Huehls
Amelia M. Huehls
AKArun Kanakkanthara
Arun Kanakkanthara
LKLarry M. Karnitz
Larry M. Karnitz
Tumors with defective homologous recombination (HR) DNA repair are more sensitive to chemotherapies that induce lesions repaired by HR as well as PARP inhibitors (PARPis). However, these therapies have limited activity in HR-proficient cells. Accordingly, agents that disrupt HR may be a means to augment the activities of these therapies in HR-proficient tumors. Here we show that VLX600, a small molecule that has been in a phase I clinical trial, disrupts HR and synergizes with PARPis and platinum compounds in ovarian cancer cells. We further found that VLX600 and other iron chelators disrupt HR, in part, by inhibiting iron-dependent histone lysine demethylases (KDM) family members, thus blocking recruitment of HR repair proteins, including RAD51, to double-strand DNA breaks. Collectively, these findings suggest that pharmacologically targeting KDM family members with VLX600 may be a potential novel strategy to therapeutically induce HR defects in ovarian cancers and correspondingly sensitize them to platinum agents and PARPis, two standard-of-care therapies for ovarian cancer.

3 April 2023
Verified
Other
Open access
TEThomas L. Ekstrom
Thomas L. Ekstrom
NPNicholas M. Pathoulas
Nicholas M. Pathoulas
AHAmelia M. Huehls
Amelia M. Huehls
AKArun Kanakkanthara
Arun Kanakkanthara
LKLarry M. Karnitz
Larry M. Karnitz
Tumors with defective homologous recombination (HR) DNA repair are more sensitive to chemotherapies that induce lesions repaired by HR as well as PARP inhibitors (PARPis). However, these therapies have limited activity in HR-proficient cells. Accordingly, agents that disrupt HR may be a means to augment the activities of these therapies in HR-proficient tumors. Here we show that VLX600, a small molecule that has been in a phase I clinical trial, disrupts HR and synergizes with PARPis and platinum compounds in ovarian cancer cells. We further found that VLX600 and other iron chelators disrupt HR, in part, by inhibiting iron-dependent histone lysine demethylases (KDM) family members, thus blocking recruitment of HR repair proteins, including RAD51, to double-strand DNA breaks. Collectively, these findings suggest that pharmacologically targeting KDM family members with VLX600 may be a potential novel strategy to therapeutically induce HR defects in ovarian cancers and correspondingly sensitize them to platinum agents and PARPis, two standard-of-care therapies for ovarian cancer.

3 April 2023
Verified
Other
Open access
TEThomas L. Ekstrom
Thomas L. Ekstrom
NPNicholas M. Pathoulas
Nicholas M. Pathoulas
AHAmelia M. Huehls
Amelia M. Huehls
AKArun Kanakkanthara
Arun Kanakkanthara
LKLarry M. Karnitz
Larry M. Karnitz
Supplementary Figures S1-S7, figure legends, and Tables S1 and S2.